| Drug Name: | Carvedilol (72956-09-3) |
|---|---|
| PubChem ID: | 2585 |
| SMILES: | COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O |
| InchiKey: | OGHNVEJMJSYVRP-UHFFFAOYSA-N |
| Therapeutic Category: | Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Adrenergic beta-Antagonists, Antihypertensive Agents, Cardiovascular Agents, Neurotransmitter Agents, Vasodilator Agents |
| Molecular Weight (dalton) | : | 406.482 |
| LogP | : | 3.738 |
| Ring Count | : | 4 |
| Hydrogen Bond Acceptor Count | : | 5 |
| Hydrogen Bond Donor Count | : | 3 |
| Total Polar Surface Area | : | 75.74 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Bradycardia | CYP2D6 (P10635) | Concomitant administration of clonidine with agents with b-blocking properties (carvedilol) may potentiate blood-pressure- and heart-rate-lowering effects When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated@ the b-blocking agent should be discontinued first [ ADR Type 4 ] | Comment: potential risk of valproic acid therapy in patients who are HIV-positive |
| Increased Beta-Blockade | CYP2D6 (P10635) | Increased beta-blockade [ ADR Type 1 ] | Drugs in special patient groups: clinical importance of genomics in drug effects In: Carruthers GS, Hoffmann BB,Melmon KL, Nierenberg DW |
| Left Ventricular Systolic Dysfunction | Multidrug resistance protein 1 (P08183) | Inhibition of P-gp-mediated transcellular transport of diGOxin decreased circulation volume or plasma albumin level of hemodialysis patients@ which may lead to asymptomatic left ventricular systolic dysfunction [ ADR Type 4 ] | Efficacy of additional low-dose carvedilol in maintenance hemodialysis patients with asymptomatic left ventricular systolic dysfunction |
| Slow Av Conduction | CYP2D6 (P10635) | DiGOxin concentrations are increased by about 15% when diGOxin and carvedilol are administered concomitantly becaesue of the inhibition of CYP2D6 activity by carvedilol Both diGOxin and COREG slow AV conduction [ ADR Type 4 ] | Comment: potential risk of valproic acid therapy in patients who are HIV-positive |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category